Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation

Biology of Blood and Marrow Transplantation

Volumn 12, Issue 2, 2006, Pages 217-225

  Nieto, Yago ^a   Patton, Nigel ^b   Hawkins, Timothy ^c   Spearing, Ruth ^b   Bearman, Scott I ^d   Jones, Roy B ^e   Shpall, Elizabeth J ^f   Rabinovitch, Rachel ^f   Zeng, Chan ^f   Barón, Anna ^f   McSweeney, Peter A ^d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b CANTERBURY HEALTH LABORATORIES   (New Zealand)

^c AUCKLAND CITY HOSPITAL   (New Zealand)

^d Rocky Mountain Cancer Center   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f UNIVERSITY OF COLORADO   (United States)

Author keywords

Graft versus host disease; Matched sibling donor; Mycophenolate mofetil; Nonmyeloablative transplantation; Tacrolimus

Indexed keywords

ANTIBIOTIC AGENT; FLUCONAZOLE; FLUDARABINE; LEVOFLOXACIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AGED; ARTICLE; BACTERIAL PNEUMONIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; FEMALE; GASTROINTESTINAL INFECTION; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HLA MATCHING; HUMAN; HYPERGLYCEMIA; INFECTION; KIDNEY FAILURE; LOW ENERGY RADIATION; MALE; MENTAL DISEASE; MORTALITY; MULTIPLE ORGAN FAILURE; NAUSEA; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OTITIS MEDIA; PANCREATITIS; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; SIBLING; SIDE EFFECT; TREMOR; TUMOR GROWTH; VIREMIA; VIRUS INFECTION; VIRUS REACTIVATION; VOMITING; WHOLE BODY RADIATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVING DONORS; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; SIBLINGS; STEM CELL TRANSPLANTATION; SURVIVAL RATE; TACROLIMUS; TRANSPLANTATION CONDITIONING; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 31344457787     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2005.10.012     Document Type: Article

References (30)

1. S. Giralt E. Estey M. Albitar et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy Blood 89 1997 4531-4536
2. I.F. Khouri M. Keating M. Korbling et al. Transplant-lite: Induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies J Clin Oncol 16 1998 2817-2824
3. S. Slavin A. Nagler E. Naparstek et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 91 1998 756-763
4. M. Sykes F. Preffer S. McAfee et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation Lancet 353 1999 1755-1759
5. R. Childs E. Clave N. Contentin et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses Blood 94 1999 3234-3241
6. R. Chakraverty K. Peggs R. Chopra et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen Blood 99 2002 1071-1078
7. P.A. McSweeney D. Niederwieser J.A. Shizuru et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects Blood 97 2001 3390-3400
8. D. Niederwieser M. Maris J.A. Shizuru et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases Blood 101 2003 1620-1629
9. R. Diaconescu C.R. Flowers B. Storer et al. Morbidity and mortality with nonmyeloablative compared to myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors Blood 104 2004 1550-1558
10. M.L. Sorror M.B. Maris B. Storer et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplant comorbidities Blood 104 2004 961-968
11. M. Mielcarek P.J. Martin W. Leisenring et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation Blood 102 2003 756-762
12. T. Kino H. Hatanaka S. Miyata et al. FK506, a novel immunosuppressant isolated from a Steptomyces. II. Immunosuppressive effects of FK506 in vitro J Antibiot 40 1987 1256-1265
13. V. Ratanatharathorn R.A. Nash D. Przepiorka et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation Blood 92 1998 2303-2314
14. R.A. Nash J.H. Antin C. Karanes et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors Blood 96 2000 2062-2068
15. M. Tanabe S. Todo N. Murase et al. Therapeutic synergism between low-dose FK506 and antimetabolites in rat allogeneic heart transplantation Transplant Proc 27 1995 364-365
16. K. Zucker A. Rosen A. Tsaroucha et al. Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings Transplant Immunol 5 1997 225-232
17. S. Gregoor R. de Sevaux R. Hene et al. Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients Transplantation 68 1999 1603-1606
18. T. Van Gelder J. Klupp M.J. Barten et al. Co-administration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but co-administration of cyclosporine inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure J Heart Lung Transplant 20 2001 160-161
19. D. Przepiorka D. Weisdorf P. Martin et al. Consensus conference on acute GVHD grading Bone Marrow Transplant 15 1995 825-828
20. K.M. Sullivan E. Agura C. Anasetti et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation Semin Hematol 18 1991 250-259
21. M.E.D. Flowers F. Traina B. Storer et al. Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning Bone Marrow Transplant 35 2005 277-282
22. Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients MMWR Recomm Rep 49 2000 1-125
23. E.L. Kaplan P. Meier Nonparametric estimation from incomplete observations JAMA 53 1958 457-481
24. M. Mielcarek L. Burroughs W. Leisenring et al. Prognostic relevance of "early-onset" graft-versus-host disease following non-myeloablative haematopoietic cell transplantation Br J Haematol 129 2005 381-391
25. F. Baron M.B. Maris B.M. Sandmaier et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning J Clin Oncol 23 2005 1993-2003
26. Y. Nieto P. Russ G. Everson et al. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation Bone Marrow Transplant 26 2000 109-111
27. C. Junghanss M. Boeckh R.A. Carter et al. Incidence and outcome of cytomegalovirus infections following nonmyeloablative compared with myeloablative allogeneic stem cell transplantation, a matched control study Blood 99 2002 1978-1985
28. T. Fukuda M. Boeckh R.A. Carter et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning Blood 102 2003 827-833
29. L. Burroughs W. Leisenring D.G. Maloney et al. Extending postgrafting cyclosporine does not decrease the risk of graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation [abstract] Blood 2003 102a
30. P.A. McSweeney S. Abhyankar J. Foran et al. Favorable early transplant outcomes using tacrolimus and mycophenolate mofetil for GVHD prevention after matched sibling allografting [abstract] Blood 102 2003 714a